Actavis To Pay $66 Billion For Allergan, Establishing A “Growth Pharma”
This article was originally published in The Pink Sheet Daily
Executive Summary
The generics giant, after buying Forest, is further diversifying into specialty pharma with the acquisition of Botox marketer Allergan for $219 per share. Valeant said it doesn’t plan to counter.